1. Home
  2. DKI vs INTS Comparison

DKI vs INTS Comparison

Compare DKI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DKI

DarkIris Inc. Class A Ordinary Shares

HOLD

Current Price

$3.96

Market Cap

10.0M

Sector

N/A

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$4.95

Market Cap

11.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DKI
INTS
Founded
2018
2012
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
11.4M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
DKI
INTS
Price
$3.96
$4.95
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$38.00
AVG Volume (30 Days)
85.4K
27.6K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.22
52 Week High
$11.80
$8.06

Technical Indicators

Market Signals
Indicator
DKI
INTS
Relative Strength Index (RSI) 39.08 N/A
Support Level $3.50 N/A
Resistance Level $5.20 N/A
Average True Range (ATR) 0.39 0.00
MACD 0.02 0.00
Stochastic Oscillator 19.78 0.00

Price Performance

Historical Comparison
DKI
INTS

About DKI DarkIris Inc. Class A Ordinary Shares

Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: